908 Devices Inc.

908 Devices Inc.

MASS·NASDAQ

$8.66

-2.1%
HealthcareMedical - Devices

908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry (Mass Spec) devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of gas, liquid, and solid materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. It operates in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts.

At a Glance

Live Snapshot
Market Cap$327.47M
EPS0.5400
P/E Ratio16.04
Earnings Date08/04/2026

SEC Filings

MASS - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
10-Q

10-Q 2026 Q1

Q1

May 06, 2026
March 31, 2026
2026
8-K

8-K 2026

N/A

May 06, 2026
May 04, 2026
2026
DEF 14A

DEF 14A 2026

N/A

April 29, 2026
June 11, 2026
2026
S-3

S-3

N/A

March 09, 2026
March 09, 2026
 
10-K

10-K 2025 FY

FY

March 09, 2026
December 31, 2025
2025
8-K

8-K 2026

N/A

March 03, 2026
March 03, 2026
2026
8-K

8-K 2026

N/A

January 20, 2026
January 20, 2026
2026
10-Q

10-Q 2025 Q3

Q3

November 10, 2025
September 30, 2025
2025
8-K

8-K 2025

N/A

November 10, 2025
November 10, 2025
2025
10-Q

10-Q 2025 Q2

Q2

August 05, 2025
June 30, 2025
2025
Showing 1 to 10 of 79 filings

Understanding SEC Filings

Essential regulatory documents for investors

SEC filings are mandatory documents that publicly traded companies must submit to the Securities and Exchange Commission. These reports provide critical insights into a company's financial health, operations, risks, and strategic direction. For investors conducting due diligence, these filings are the most authoritative source of company information.

10-K

Annual Report

Comprehensive annual financial report filed within 60-90 days of fiscal year-end. Includes audited financial statements, management discussion & analysis (MD&A), risk factors, and detailed business operations. The most thorough financial disclosure of the year.

Filed annually
10-Q

Quarterly Report

Unaudited quarterly financial report filed within 40-45 days after each of the first three fiscal quarters. Provides updates on financial position, results of operations, and significant events. Essential for tracking quarterly performance trends.

Filed 3 times per year
8-K

Current Report

Event-driven filing for material events that shareholders should know about, filed within 4 business days. Includes acquisitions, executive changes, bankruptcy, earnings releases, and other significant developments. Critical for staying informed about breaking news.

Filed as events occur
DEF 14A

Proxy Statement

Definitive proxy statement sent to shareholders before annual meetings. Contains executive compensation details, board member information, voting matters, and corporate governance policies. Key for understanding management incentives and board composition.

Filed before shareholder meetings
S-1

Registration Statement

Initial registration for securities offerings, including IPOs. Provides detailed company history, business model, financial statements, risk factors, and use of proceeds. Essential for evaluating new investment opportunities and understanding company fundamentals.

Filed for new offerings
20-F

Foreign Annual Report

Annual report for foreign private issuers, equivalent to Form 10-K for non-U.S. companies. Filed within 4-6 months of fiscal year-end. Contains audited financials, business description, and regulatory disclosures adapted for international companies.

Foreign companies only

Why SEC Filings Matter

  • Regulatory Accuracy: Filings are subject to SEC review and legal penalties for misstatements, ensuring high data quality
  • Management Insights: MD&A sections reveal management's perspective on trends, challenges, and future outlook
  • Risk Assessment: Detailed risk factor disclosures help investors understand potential threats to business operations
  • Competitive Analysis: Business descriptions and segment data enable comparison with industry peers
  • Historical Context: Years of filings provide trend analysis and context for current performance